Cognito Therapeutics
CAMBRIDGE, Massachusetts · Healthcare, Health Care, Manufacturing
Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease.
Key facts
- Headquarters
- CAMBRIDGE, Massachusetts
- Employees
- 57
- Industries
- Healthcare, Health Care, Manufacturing
- Status
- Private
- Website
- cognitotx.com
- Company page
Recent activity at Cognito Therapeutics
- : Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President
- : Cognito Therapeutics secures $105 million in Series C funding led by Morningside Ventures to advance Spectris™ in Alzheimer’s disease.
- : Cognito Therapeutics Group
- : Cognito Therapeutics Appoints Christian Howell as Chief Executive Officer
- : Cognito Therapeutics Ltd
- : Cognito Therapeutics raises $35M Series B extension
- : Cognito Therapeutics Ltd
- : Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer
- : Cognito Therapeutics Scores $73M Series B
- : Cognito Therapeutics Ltd.
Cognito Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Series C | $105.0M |
| Apr 2025 | Venture | $196.3M |
| Jul 2024 | Venture | $10.2M |
| Jan 2024 | Series B | $35.0M |
| Nov 2023 | Venture | $108.8M |
Leadership
- Thomas Fagan, Executive Vice President
- Christian Howell, Chief Executive Officer
- Ralph Kern, Chief Medical Officer
- Brent Vaughan, Chief Executive Officer
- Christian Howell, Chief Commercial Officer
Verified email and direct lines for Cognito Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Cognito Therapeutics in the news
- Cognito Therapeutics moves to drop ‘dementia’ from its comms, scientific materials - Fierce Pharma (Apr 08, 2026)
- Cognito Therapeutics and Ochsner Health Launch Brain Health Collaboratory to Advance New Care Models for Alzheimer’s Disease - Business Wire (Mar 25, 2026)
- WVU Rockefeller Neuroscience Institute and Cognito Therapeutics launch Brain Health Collaboratory to accelerate neurotherapies with AI-powered research - WVU Medicine (Nov 13, 2025)
- First Digital Therapeutic Improves Memory, Cognition, Functional Abilities in Alzheimer Disease - NeurologyLive (Mar 12, 2021)
- Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing to Advance Spectris™ in Alzheimer’s Disease - Business Wire (Mar 05, 2026)
- Cognito Therapeutics to Present New Data Highlighting Effects of Spectris™ on Lipid Transport Biomarkers in Alzheimer’s Disease at AAIC 2026 - Business Wire (Jun 22, 2026)
- Cognito Therapeutics Presents Exploratory Biomarker Data at AAIC 2026 Supporting Coordinated Modulation of Lipid Transport and Myelination Pathways - Business Wire (Jul 13, 2026)
- Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease - Business Wire (Mar 22, 2023)
Companies similar to Cognito Therapeutics
- Omniscient Neurotechnology · Healthcare, Health Care, Manufacturing
- Novabay · Healthcare, Health Care, Manufacturing
- ivWatch · Healthcare, Health Care, Manufacturing
- Shape Memory Medical · Healthcare, Health Care, Manufacturing
- NOWDiagnostics, Inc. · Healthcare, Health Care, Manufacturing
About Cognito Therapeutics: questions and answers
What does Cognito Therapeutics do?
Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease.
Where is Cognito Therapeutics headquartered?
Cognito Therapeutics is headquartered in CAMBRIDGE, Massachusetts.
How many employees does Cognito Therapeutics have?
Cognito Therapeutics has about 57 employees.
Has Cognito Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for Cognito Therapeutics. The most recent, Series C of $105.0M, was in Mar 2026.
Who leads Cognito Therapeutics?
Thomas Fagan is an Executive Vice President at Cognito Therapeutics.
What is the latest news on Cognito Therapeutics?
On Mar 11, 2026, Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy